[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 7, Issue 4 (12-2005) ::
2005, 7(4): 347-354 Back to browse issues page
Anti Cardiolipin antibody in Type I diabetic patients
M Tohidi , F Hadaegh , H Harati , AR Sobhani , M Farshadi , P Esteaneh
, tohidimaryam@yahoo.com
Abstract:   (21099 Views)
Aims: Type 1 diabetes mellitus is an autoimmune disorder which is associated with different organ specific autontibodies including anticardiolipin antibody (ACLA). The association of ACLA with diabetes has not been widely reported. The aim of this study was to determine the prevalence of ACLA IgG and IgM and evaluation of their possible association with other auto-antibodies, duration of disease and status of control of blood glucose in type 1 diabetes patients. Materials and Methods: In a cross sectional study, 48 patients with type 1 diabetes in Bandar Abbas were compared with 41 age & sex matched healthy persons for the presence of ACLA (IgG and IgM), Rheumatoid Factor (RF) and Anti Nuclear Antibody. Results: The mean age of diabetic patients was 20/5 ± 10 years. High titers of ACLA (IgG and/or IgM) were more common in type 1 diabetic patients than in healthy controls (18% vs. 0%, p<0.01) with no significant difference between males and females (4 and 12% respectively). Unlike ACLA IgG, the mean value of serum ACLA IgM was significantly higher in type 1 diabetic patients than in controls (6.8±2.8 vs. 4.5±2.4 GPLU/ml). Among type 1 diabetic patients, those with high titers of ACLA (ACLA+) were older and had higher age of onset of diabetes than those with normal titers, but there were no difference in duration of diabetes or level of HbA1c between them. No significant difference was observed in the prevalence of ACLA+ or the mean values of ACLA IgG and IgM between recently (< 1 years) and previously (> 1 years) diagnosed diabetic patients. ACLA+ patients were also more likely to show positive RF than the ACLA- group(25 vs. 0%). Conclusion: The relatively high prevalence of ACLA (+) in type 1 diabetic patients and its association with other autoantibodies may reflect an abnormal immunologic response in some stages of type 1 diabetes. ACLA might be added to the list of autoantibodies that should be measured in type 1 diabetes patients.
Keywords: Anticardiolipin antibody, Type 1 diabetes.
Full-Text [PDF 280 kb]   (4718 Downloads)    
Type of Study: Original | Subject: Endocrinology
Received: 2006/11/15 | Published: 2005/12/15
Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Tohidi M, Hadaegh F, Harati H, Sobhani A, Farshadi M, Esteaneh P. Anti Cardiolipin antibody in Type I diabetic patients. Iranian Journal of Endocrinology and Metabolism 2005; 7 (4) :347-354
URL: http://ijem.sbmu.ac.ir/article-1-90-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 7, Issue 4 (12-2005) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.05 seconds with 38 queries by YEKTAWEB 4624